MX359329B - Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. - Google Patents
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.Info
- Publication number
- MX359329B MX359329B MX2014005139A MX2014005139A MX359329B MX 359329 B MX359329 B MX 359329B MX 2014005139 A MX2014005139 A MX 2014005139A MX 2014005139 A MX2014005139 A MX 2014005139A MX 359329 B MX359329 B MX 359329B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment protocol
- diabetes type
- diabetes
- type
- protocol
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a una combinación farmacéutica, para usarse en el tratamiento de un paciente que padece diabetes tipo 2, en donde la diabetes tipo 2 se controla de manera insuficiente por medio de por lo menos un fármaco antidiabético oral, dicha combinación comprende (a) desPro36Exendina-4(1-39)-Lys 6-NH2 y/o una sal farmacéuticamente aceptable del mismo, (b) insulina glargina y/o una sal farmacéuticamente aceptable de la misma, y (c) metformina y/o una sal farmacéuticamente aceptable de la misma, en donde el tratamiento del paciente que padece de diabetes tipo 2 comprende las etapas de: (i) administrar los compuesto (b) y (c) durante por lo menos 4 semanas, con la condición de que el compuesto (a) no se administre, y (ii) continuar el tratamiento de administrar los compuestos (a), (b) y (c), en donde al inicio de la etapa (i), el paciente tiene una concentración de glucosa plasmática posprandial a dos hora de por lo menos 12 mmol/L, y una excursión glucémica de por lo menos 5 mmol/L, en donde la excursión glucémica es la diferencia de la concentración de glucosa plasmática posprandial a dos horas y de la concentración de glucosa plasmática 30 minutos antes de una comida de prueba, y en donde la cantidad del compuesto (b) que se administrará en las etapas (i) y/o (ii) se ajusta para alcanzar o por lo menos estar aproximada a un predeterminado nivel del glucosa plasmática en ayunas y/o un predeterminado nivel del glucosa plasmática auto-supervisada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11187169 | 2011-10-28 | ||
| PCT/EP2012/071271 WO2013060850A1 (en) | 2011-10-28 | 2012-10-26 | Treatment protocol of diabetes type 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005139A MX2014005139A (es) | 2014-08-27 |
| MX359329B true MX359329B (es) | 2018-09-25 |
Family
ID=47071308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005139A MX359329B (es) | 2011-10-28 | 2012-10-26 | Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130296236A1 (es) |
| EP (1) | EP2771024B1 (es) |
| JP (1) | JP6329487B2 (es) |
| KR (1) | KR101967941B1 (es) |
| CN (2) | CN104066441A (es) |
| AU (1) | AU2012328388B2 (es) |
| BR (1) | BR112014010200A2 (es) |
| CA (1) | CA2851690C (es) |
| IL (1) | IL232251B (es) |
| IN (1) | IN2014CN02616A (es) |
| MX (1) | MX359329B (es) |
| MY (1) | MY170713A (es) |
| RU (1) | RU2014121386A (es) |
| SG (1) | SG11201401175SA (es) |
| WO (1) | WO2013060850A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| EP3202394A1 (de) | 2009-07-06 | 2017-08-09 | Sanofi-Aventis Deutschland GmbH | Wässrige insulinzubereitungen enthaltend methionin |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
| PT2554183T (pt) | 2009-11-13 | 2018-07-09 | Sanofi Aventis Deutschland | Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina |
| US20140148384A1 (en) | 2010-08-30 | 2014-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| US20160038077A1 (en) * | 2013-06-27 | 2016-02-11 | Inspark Technologies, Inc. | Systems, Devices, and/or Methods for Identifying Time Periods of Insufficient Blood Glucose Testing |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| CN105899191B (zh) | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
| RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
| KR20160104724A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI706779B (zh) * | 2015-01-16 | 2020-10-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 小兒第２型糖尿病病患之治療 |
| TWI748945B (zh) * | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) * | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| WO2025124473A1 (zh) * | 2023-12-12 | 2025-06-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物治疗代谢疾病的方法及医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| MXPA06002127A (es) * | 2003-09-02 | 2006-05-31 | Prosidion Ltd | Terapia combinada para control glucemico. |
| AU2005271526B2 (en) * | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| US20120053843A1 (en) * | 2009-02-04 | 2012-03-01 | Sanofi-Aventis Deutschland Gmbh | Medical device and method for providing information for glycemic control |
| EP2329848B2 (en) * | 2009-11-13 | 2019-06-19 | Sanofi-Aventis Deutschland GmbH | Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| KR20110052990A (ko) * | 2009-11-13 | 2011-05-19 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법 |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
-
2012
- 2012-10-26 BR BR112014010200-7A patent/BR112014010200A2/pt not_active Application Discontinuation
- 2012-10-26 MX MX2014005139A patent/MX359329B/es active IP Right Grant
- 2012-10-26 JP JP2014537630A patent/JP6329487B2/ja active Active
- 2012-10-26 MY MYPI2014000971A patent/MY170713A/en unknown
- 2012-10-26 SG SG11201401175SA patent/SG11201401175SA/en unknown
- 2012-10-26 KR KR1020147011152A patent/KR101967941B1/ko active Active
- 2012-10-26 AU AU2012328388A patent/AU2012328388B2/en active Active
- 2012-10-26 CN CN201280065132.1A patent/CN104066441A/zh active Pending
- 2012-10-26 RU RU2014121386/15A patent/RU2014121386A/ru unknown
- 2012-10-26 US US13/661,476 patent/US20130296236A1/en not_active Abandoned
- 2012-10-26 CN CN201711071123.4A patent/CN107693783A/zh active Pending
- 2012-10-26 EP EP12775720.1A patent/EP2771024B1/en active Active
- 2012-10-26 WO PCT/EP2012/071271 patent/WO2013060850A1/en not_active Ceased
- 2012-10-26 IN IN2616CHN2014 patent/IN2014CN02616A/en unknown
- 2012-10-26 CA CA2851690A patent/CA2851690C/en active Active
-
2014
- 2014-04-24 IL IL23225114A patent/IL232251B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20130296236A1 (en) | 2013-11-07 |
| IL232251A0 (en) | 2014-06-30 |
| KR101967941B1 (ko) | 2019-04-10 |
| CA2851690C (en) | 2022-07-26 |
| CN107693783A (zh) | 2018-02-16 |
| EP2771024B1 (en) | 2018-11-28 |
| JP2015501314A (ja) | 2015-01-15 |
| CN104066441A (zh) | 2014-09-24 |
| RU2014121386A (ru) | 2015-12-10 |
| EP2771024A1 (en) | 2014-09-03 |
| MY170713A (en) | 2019-08-27 |
| JP6329487B2 (ja) | 2018-05-23 |
| HK1198577A1 (en) | 2015-04-30 |
| BR112014010200A2 (pt) | 2020-10-27 |
| SG11201401175SA (en) | 2014-09-26 |
| WO2013060850A1 (en) | 2013-05-02 |
| KR20140093935A (ko) | 2014-07-29 |
| AU2012328388B2 (en) | 2017-06-15 |
| MX2014005139A (es) | 2014-08-27 |
| CA2851690A1 (en) | 2013-05-02 |
| IN2014CN02616A (es) | 2015-06-26 |
| AU2012328388A1 (en) | 2014-05-15 |
| IL232251B (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| AP2014007436A0 (en) | A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes | |
| EA033455B1 (ru) | Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе | |
| MX370264B (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| MX2015002487A (es) | Proceso para la preparacion de teneligliptina. | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| MX366636B (es) | Nuevo derivado de un análogo de insulina. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| IN2014DN06964A (es) | ||
| PL2901857T3 (pl) | Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu | |
| MX357656B (es) | Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias. | |
| IL225755B (en) | amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain | |
| MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. | |
| UA103197C2 (uk) | Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами | |
| GEP201706636B (en) | Galactagogue compositions based on phosphatidylserine | |
| EA033160B1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| MX2011011180A (es) | Compuestos que tienen efecto fisiologico. | |
| WO2011161295A3 (es) | Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular | |
| MD4291B1 (ro) | Preparat medicamentos pentru tratamentul otitelor | |
| IN2014DN10683A (es) | ||
| MX356969B (es) | Producto lácteo bajo en colesterol para usarse en el tratamiento y/o prevención de una enfermedad hepática. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |